Skip to content
★ Sign in to follow
CA

Charles A. Hart

Executive
U.S. Stem Cell, Inc.
Total declarations
9
Company
1
▲ Purchases (6 ops.)
€200k
▼ Sales (0 ops.)
—

Latest filing published 06 Aug 2014 for U.S. Stem Cell, Inc., €1,317.

Insider track record

Disclosed buys
6
Disclosed sells
0
Signal history

No signal scores available.

Closed purchases

Market purchases
6
Positive at T+90
0%
Median T+90
-52.3%

Based on 5 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.

Purchases by company

Since each purchase

  • Filed 10 Feb 2012 · 5385 days ago · €38k
    -68.6%
    Entry US$57.00 · Close at T+365 US$17.90
  • Filed 17 Dec 2010 · 5805 days ago · €77k
    -89.8%
    Entry US$400.00 · Close at T+365 US$41.00
  • Filed 06 Dec 2010 · 5816 days ago · €21k
    -87.5%
    Entry US$440.00 · Close at T+365 US$55.00
  • Filed 14 Apr 2010 · 6052 days ago · €2,824
    -77.8%
    Entry US$900.00 · Close at T+365 US$200.00
  • Filed 05 Mar 2010 · 6092 days ago · €40k
    -66.7%
    Entry US$600.00 · Close at T+365 US$200.00

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Charles A. Hart: trading record in brief

Charles A. Hart is a declared insider of U.S. Stem Cell, Inc., with filings sourced from SEC (Form 4). Between 4 March 2010 and 25 July 2014, the trades on record add up to 9 filings.

The open-market record is one-sided, with 6 purchases worth €200k and not one sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.

The median purchase comes to €29k. After 5 purchases with a full 90-day history, the hit rate stands at 0% and the median 90-day move at -52.3%. Past outcomes like these are no guarantee of what comes next.

Most recently, on 6 August 2014, the filings show a transaction worth €1,317 in U.S. Stem Cell, Inc. The last purchase on record was published on 10 February 2012, which is 5,385 days ago. Typically, a trade is published a median of 6 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.

Companies and markets linked to Charles A. Hart

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations7 total
  • ●
    DirectorExecutivesU.S. Stem Cell, Inc.
    1,773 USD0SEC
    44,328 shares@ US$0.04Common StockSEC:0001145443-14-001007:0
  • ●
    DirectorExecutivesU.S. Stem Cell, Inc.
    27,939 USD0SEC
    1,995,614 shares@ US$0.014Common Stock Conversion of debt to equitySEC:0001145443-13-002323:0
  • ▲
    DirectorExecutivesU.S. Stem Cell, Inc.
    50,000 USD0SEC
    3,571,430 shares@ US$0.014Common StockSEC:0001388431-12-000005:0
    Canonical exit: 6 May 2012 (T+90)
  • ▲
    DirectorExecutivesU.S. Stem Cell, Inc.
    101,337 USD0SEC
    675,580 shares@ US$0.15Common StockSEC:0001388431-10-000023:0
    Canonical exit: 13 Mar 2011 (T+90)
  • ▲
    DirectorExecutivesU.S. Stem Cell, Inc.
    27,093 USD0SEC
    180,620 shares@ US$0.15Common StockSEC:0001388431-10-000022:0
    Canonical exit: 28 Feb 2011 (T+90)
  • ▲
    DirectorExecutivesU.S. Stem Cell, Inc.
    3,888 USD0SEC
    7,200 shares@ US$0.54Common StockSEC:0001388431-10-000015:0
    Canonical exit: 14 Jun 2010 (T+90)
  • ▲
    DirectorExecutivesU.S. Stem Cell, Inc.
    54,998 USD0SEC
    103,770 shares@ US$0.53Common StockSEC:0001388431-10-000014:0
    Canonical exit: 2 Jun 2010 (T+90)

7 of 7 declarations